SCHEMBL8429960

SCHEMBL8429960

N=C(c1ccc(Cl)cc1)C(N)CC1CCCC1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A2 P23975 2/20 0.40
SLC6A4 P31645 2/20 0.40
SLC6A3 Q01959 2/20 0.40
TDP1 Q9NUW8 1/20 0.40
KDM4E B2RXH2 1/20 0.39
LMNA P02545 1/20 0.38
METAP2 P50579 3/20 0.37
METAP1 P53582 1/20 0.36
NPC1 O15118 1/20 0.35
RAB9A P51151 1/20 0.35
AGER Q15109 1/20 0.35
GRN P28799 1/20 0.35
SORT1 Q99523 1/20 0.35
OPRM1 P35372 1/20 0.35
OPRL1 P41146 1/20 0.35
ADAMTS4 O75173 1/20 0.34
ADAMTS5 Q9UNA0 1/20 0.34
CYP1A2 P05177 1/20 0.33
EPHX1 P07099 1/20 0.33
HRH2 P25021 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8434495 0.81 SLC6A2 (0.40) SLC6A2SLC6A4SLC6A3TDP1KDM4E
SCHEMBL2770616 0.75 TDP1 (0.46) SLC6A2SLC6A4SLC6A3TDP1KDM4E
SCHEMBL23709460 0.70 NPC1 (0.49) SLC6A2SLC6A4SLC6A3TDP1KDM4E
SCHEMBL8247864 0.70 SLC6A2 (0.51) SLC6A2SLC6A4SLC6A3TDP1METAP2
SCHEMBL2769071 0.70 SLC6A2 (0.51) SLC6A2SLC6A4SLC6A3TDP1METAP2
SCHEMBL2771876 0.69 SLC6A4 (0.52) SLC6A2SLC6A4SLC6A3METAP2METAP1
SCHEMBL8251822 0.69 SLC6A4 (0.52) SLC6A2SLC6A4SLC6A3METAP2METAP1
SCHEMBL8429957 0.69 TDP1 (0.52) TDP1KDM4ELMNANPC1RAB9A
SCHEMBL10633563 0.67 SLC6A2 (0.54) SLC6A2SLC6A4SLC6A3METAP2NPC1
SCHEMBL5463403 0.64 SLC6A4 (0.44) SLC6A2SLC6A4SLC6A3TDP1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1643989-B1 CIS-IMIDAZOLINES AS MDM2 INHIBITORS HOFFMANN LA ROCHE (CH) 2010-04-28 EP disclosed
US-20040259867-A1 CIS-imidazoles FOTOUHI NADER (US) 2004-12-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040259867-A1 CIS-imidazoles TP53, MDM2, TP53BP1 SLC6A2 4762/4885SLC6A4 4212/4885SLC6A3 4530/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.